Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07773454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07773454 · ClinicalTrials.gov record · last posted 2026-08-19

Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

Name: Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors — clinical trial record (NCT07773454)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorExelixis

Started2026-09-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.

Trial Details

NCT Number	NCT07773454
Lead Sponsor	Exelixis
Conditions	Cancer, Pediatric Cancer
Enrollment	18 participants
Start Date	2026-09-30
Primary Completion	2028-07-31 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-19